Celgene to Acquire Juno for $9B, Expanding CAR-T, TCR Presence

Celgene has agreed to acquire Juno Therapeutics for approximately $9 billion, the companies said today, catapulting the buyer into the thick of the scramble to develop CAR (chimeric antigen receptor) T-cell (CAR-T) and TCR (T cell receptor) therapeutics.Celgene opted to step up its cancer presence in CAR-T nearly a year after Juno halted development of JCAR015 , its lead CAR-T cancer immunotherapy, and terminated its Phase II ROCKET trial. That decision in March 2017 came nearly four months afte